Treatment of MPS I mice with microencapsulated cells overexpressing IDUA: effect of the prednisolone administration

References

• Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin Immunol 2008; 80: 86–100
   Google Scholar
• Baldo G, Mayer F, Martinelli B, Meyer F, Burin M, Meurer L, Tavares A, Giugliani R, Matte U. Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-L-iduronidase partially corrects visceral pathology in MPS I mice. Cytotherapy 2012; 14(7)860–7
   PubMed Web of Science ®Google Scholar
• Baruch L, Benny O, Gilert A, Ukobnik M, Itzhak OB, Machluf M. Alginate-PLL cell encapsulation system co-entrapping PLGA-microspheres for the continuous release of anti-inflammatory drugs. Biomed Microdevices 2009; 11: 1103–13
   PubMed Web of Science ®Google Scholar
• Bílková E, Imramovský A, Sedlák M. Recent advances in the design and synthesis of prednisolone and methylprednisolone conjugates. Curr Pharm Des 2011; 17(32)3577–95
   PubMedGoogle Scholar
• Bunger CM, Tiefenbach B, Jahnke A, Gerlach C, Freier T, Schmitz KP, Hopt UT, Schareck W, Klar E, de Vos P. Deletion of the tissue response against alginate-pll capsules by temporary release of coencapsulated steroids. Biomaterials 2005; 26: 2353–60
   PubMedGoogle Scholar
• Clarke LA, Wraith JE, Beck M, Kolodny EH, Pastores GM, Muenzer J, Rapoport DM, Berger KI, Sidman M, Kakkis ED, et al. Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I. Pediatrics 2009; 123: 229–40
   PubMed Web of Science ®Google Scholar
• D'Aco K, Underhill L, Rangachari L, Arn P, Cox GF, Giugliani R, Okuyama T, Wijburg F, Kaplan P. Diagnosis and treatment trends in mucopolysaccharidosis I: Findings from the MPS I Registry. Eur J Pediatr 2012; 171(6)911–19
   PubMedGoogle Scholar
• Hopwood JJ, Muller V, Smithson A, Baggett N. A fluorometric assay using 4-methylumbelliferyl alpha-L-iduronide for the estimation of alpha-L-iduronidase activity and the detection of Hurler and Scheie syndromes. Clin Chim Acta 1979; 92(2)257–65
   PubMedGoogle Scholar
• Jayant RD, McShane MJ, Srivastava R. In vitro and in vivo evaluation of anti-inflammatory agents using nanoengineered alginate carriers: Towards localized implant inflammation suppression. Int J Pharm 2011; 403(1–2)268–75
   PubMedGoogle Scholar
• Kakkis ED, Schuchman E, He X, Wan Q, Kania S, Wiemelt S, Hasson CW, O'Malley T, Weil MA, Aguirre GA, et al. Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 2001; 72(3)199–208
   PubMedGoogle Scholar
• Lagranha VL, Baldo G, de Carvalho TG, Burin M, Saraiva-Pereira ML, Matte U, Giugliani R. In vitro correction of ARSA deficiency in human skin fibroblasts from metachromatic leukodystrophy patients after treatment with microencapsulated recombinant cells. Metab Brain Dis 2008; 23(4)469–84
   PubMed Web of Science ®Google Scholar
• Lindvall O. and Wahlberg, LU. Encapsulated cell biodelivery of GDNF: A novel clinical strategy for neuroprotection and neuroregeneration in Parkinson's disease?. Exp Neurol 2008; 209: 82–8
   PubMed Web of Science ®Google Scholar
• Lowry RB, Renwick DH. Relative frequency of the Hurler and Hunter syndromes. N Engl J Med 1971; 284(4)221–2
   PubMedGoogle Scholar
• Martins AM, Dualibi AP, Norato D, Takata ET, Santos ES, Valadares ER, Porta G, de Luca G, Moreira G, Pimentel H, et al. Guidelines for the management of mucopolysaccharidosis type I. J Pediatr 2009; 155(4 Suppl.)S32–46
   PubMed Web of Science ®Google Scholar
• Mayer FQ, Baldo G, de Carvalho TG, Lagranha VL, Giugliani R, Matte U. Effects of cryopreservation and hypothermic storage on cell viability and enzyme activity in recombinant encapsulated cells overexpressing alpha-L-iduronidase. Artif Organs 2011; 34(5)434–9
   Google Scholar
• Murua A, Herran E, Orive G, Igartua M, Blanco FJ, Pedraz JL, Hernández RM. Design of a composite drug delivery system to prolong functionality of cell-based scaffolds. Int J Pharm 2011; 407(1–2)142–50
   PubMedGoogle Scholar
• Murua A, Orive G, Hernández RM, Pedraz JL. Xenogeneic transplantation of erythropoietin-secreting cells immobilized in microcapsules using transient immunosuppression. J Control Release 2009; 137: 174–8
   PubMed Web of Science ®Google Scholar
• Nakama H, Ohsugi K, Otsuki T, Date I, Kosuga M, Sakuragawa N. Encapsulation cell therapy for mucopolysaccharidosis type VII using genetically engineered immortalized human amniotic epithelial cells. Tohoku J Exp Med 2006; 209(1)23–32
   PubMedGoogle Scholar
• Omer A, Keegan M, Czismadia E, de Vos P, Van Rooijen N, Bonner-Weir S, Weir GC. Macrophage depletion improves survival of porcine neonatal pancreatic cell clusters contained in alginate macrocapsules transplanted into rats. Xenotransplantation 2003; 10: 240–51
   PubMedGoogle Scholar
• Peduto G, Rinsch C, Schneider BL, Rolland E, Aebischer P. Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosuppression. Transplantation 2000; 70(1)78–85
   PubMedGoogle Scholar
• Ponce S, Orive G, Hernández R, Gascón AR, Pedraz JL, de Haan BJ, Faas MM, Mathieu HJ, de Vos P. Chemistry and the biological response against immunoisolating alginate-polycation capsules of different composition. Biomaterials 2006; 27(28)4831–9
   PubMed Web of Science ®Google Scholar
• Ponder KP. Immune response hinders therapy for lysosomal storage diseases. J Clin Invest 2008; 118(8)2686–9
   PubMed Web of Science ®Google Scholar
• Robitaille R, Dusseault J, Henley N, Desbiens K, Labrecque N, Hallé JP. Inflammatory response to peritoneal implantation of alginate-poly-L-lysine microcapsules. Biomaterials 2005; 26(19)4119–27
   PubMedGoogle Scholar
• Ross CJD, Ralph M, Chang PL. Somatic gene therapy for a neurodegenerative disease using microencapsulated recombinant cells. Exp Neurol 2000; 166: 276–86
   PubMed Web of Science ®Google Scholar
• Tam SK, de Haan BJ, Faas MM, Hallé JP, Yahia L, de Vos P. Adsorption of human immunoglobulin to implantable alginate-poly-L-lysine microcapsules: Effect of microcapsule composition. J Biomed Mater Res A 2009; 89(3)609–15
   PubMedGoogle Scholar
• Tylki-Szymanska A, Marucha J, Jurecka A, Syczewska M, Czartoryska M. Efficacy of recombinant human α-L-iduronidase (laronidase) on restricted range of motion of upper extremities in mucopolysaccharidosis type I patients. J Inherit Metab Dis 2010; 33: 151–7
   PubMedGoogle Scholar
• Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology 2011; 50(Suppl. 5)v49–59
   Google Scholar
• Viana FAB. Guia Terapêutico Veterinário2nd. Gráfica e Editora CEM, Lagoa Santa 2007
   Google Scholar
• Visted T, Bjerkvig R, Enger PO. Cell encapsulation technology as a therapeutic strategy for CNS malignancies. Neuro Oncol 2001; 3: 201–10
   PubMed Web of Science ®Google Scholar
• Yoshida H, Date I, Shingo T, Fujiwara K, Miyoshi Y, Furuta T, Ohmoto T. Evaluation of reaction of primate brain to grafted PC12 cells. Cell Transplant 1999; 8: 427–30
   PubMedGoogle Scholar